|
|
Article: HUMIRA(R) Subcutaneous Injection 40mg Syringe 0.8mL Now Available for the Treatment of Rheumatoid Arthritis.
- Article from:
- JCN Newswires
- Article date:
- June 18, 2008
CopyrightCOPYRIGHT 2008 Japan Corporate News Network K.K. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Tokyo, June 17, 2008 - (JCN Newswire) - On June 17, 2008, Abbott Japan Co., Ltd. (Pharmaceutical Products Group in Tokyo, President: Glenn S. Warner) and Eisai Co., Ltd. (Headquarters in Tokyo, President and CEO: Haruo Naito) announced that HUMIRA(R) subcutaneous injection 40mg Syringe 0.8mL (referred to as HUMIRA hereinafter) will be available for the treatment of rheumatoid arthritis from June 18, 2008.
HUMIRA received approval for manufacturing and distribution in Japan on April 16, 2008, and was listed in the National Health Insurance drug price list on June 13, 2008. After its launch, Abbott and Eisai will take a one-brand, one-channel and two-promotion ...